Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
NKTR-214 · 1 trial · 1 indication
This outcome quantifies the number and types of adverse events associated with NKTR-214.
The data below reflects the incidence of Dose Limiting Toxicity Events observed in this trial.
| Arm | Type | Description |
|---|---|---|
| NKTR-214 Dose Escalation | EXPERIMENTAL | This is a first in human, open-label, sequential dose escalation and expansion Phase 1 study of NKTR--214 in adult patients with locally advanced and metastatic solid tumors. The Phase 1 stage of the study is designed as an open-label dose escalation trial of NKTR--214 in participants with locally advanced or metastatic solid tumors. The goal of the dose escalation stage of the study is to find the recommended phase 2 dose, to evaluate the efficacy of NKTR--214 by assessing the objective response rate and to evaluate the safety of NKTR-214. Immunological biomarkers in plasma and tumor samples will also be measured. |
| Name | Type | Description |
|---|---|---|
| NKTR-214 | DRUG | Participants in the dose escalation cohorts will be treated every 21 days (q21d) or every 14 days (q14d) until tumor progression. |
Inclusion Criteria: * Histologically confirmed diagnosis of a locally advanced or metastatic solid tumor. * Received 1 or 2 prior lines of therapy. * Life expectancy \>12 weeks. * Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1. * Measurable disease per RECIST v1.1. * Demonstrat...
NKTR-214 is an investigational small molecule being studied for the treatment of unspecified adult solid tumors, as defined by the specific protocol. It is in Phase 1 clinical development for oncology indications.
NKTR-214 is being developed by Nektar Therapeutics, a biopharmaceutical company. The company's ticker symbol is NKTR.
NKTR-214 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 1 trial has been completed.
NKTR-214 has been studied in a Phase 1/2 multicenter dose escalation and expansion trial (NCT02869295) in subjects with locally advanced or metastatic solid tumors. This trial, conducted in the United States, enrolled 28 participants and has been completed.
NKTR-214 is also known as bempegaldesleukin. It is an investigational small molecule being developed by Nektar Therapeutics for the treatment of solid tumors.